FDA Panel Endorses Class II Status for Surgical Mesh Instrumentation
This article was originally published in The Gray Sheet
The Gastroenterology and Urology Devices Panel supported FDA’s proposal to up-classify surgical mesh instrumentation from class I to class II with special controls.
You may also be interested in...
The US agency has agreed with an earlier assessment by an advisory panel last year to up-classify surgical mesh instrumentation by issuing a Jan. 6 final order to move the instrumentation – used for women undergoing pelvic organ prolapse or female stress incontinence procedures – from class I to class II.
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.